Serum Institute of India

Pune: Serum Institute of India (SII) has decided to apply for emergency authorisation of COVID-19 vaccine in the next two weeks, chief executive Adar Poonawalla said on Saturday. The Pune-based company has partnered with global pharma…

New Delhi: Prime Minister Narendra Modi will visit India’s three pharma majors on Saturday to personally review the development of COVID-19 vaccine and the manufacturing process. “As India enters a decisive phase of the fight against…

New Delhi: The Pune-based Serum Institute of India (SII) has said the COVID-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly with strict adherence to all…

Pune: Prime Minister Narendra Modi will visit Pune-based Serum Institute of India (SII), which has partnered with global pharma giant AstraZeneca and Oxford University for a COVID-19 vaccine candidate, on Saturday. “We have received a…

New Delhi: Every Indian will get vaccinated, probably by 2024, said Serum Institute of India’s (SII) CEO Adar Poonawalla. The Oxford COVID-19 vaccine will be priced at a maximum of Rs 1,000 for two necessary doses for the public, (depending…

Pune: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday raised some serious concerns regarding the production and distribution of COVID-19 vaccine in the country. Poonawalla asked whether the Indian government will have Rs…

Pune: The Serum Institute of India (SII) will start the third and final phase of human trial of Oxford-Astrazeneca’s coronavirus vaccine at Pune’s Sasson General Hospital early next week. “The phase III trial of ‘Covishield’ vaccine will…

New Delhi: A coronavirus vaccine will be available in the country by the beginning of next year, Union Health Minister Harsh Vardhan told the Rajya Sabha on Thursday. “Just like other countries, India is also making efforts. Three vaccines…

New Delhi: The Drugs Controller General of India (DCGI) has given permission to Serum Institute of India, a Pune-based vaccine maker, to resume the Phase 2 and Phase 3 clinical trials of the COVID-19 vaccine in the country. DCGI had halted…

Pune: Serum Institute of India’s (SII) phase 2 trial of Oxford's COVID-19 vaccine candidate is set to commence on Tuesday. The determination of safety and immunogenicity of “Covishield” on healthy Indian adults will start at Bharati…